Initial outcomes data from Cleveland Clinic’s Medical Intensive Liver Unit shows significantly improved survival rates for the first 185 cirrhotic patients managed in the new facility.
Patients with inflammatory conditions and concomitant cirrhosis who are treated with tumor necrosis factor inhibitors face heightened risk of serious infections and other complications, according to new Cleveland Clinic research.
Miguel Regueiro, MD, Chair of Cleveland Clinic’s Department of Gastroenterology, Hepatology and Nutrition, highlights six can’t-miss DDW presentations by our researchers.
Researchers presented today at ACG 2018 that the MELD-Na score is a reliable predictor for risk stratification and survival after emergent transjugular intrahepatic portosytemic shunt (TIPS) placement.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic study presented at WCOG at ACG2017 shows patients with cirrhosis and severe pancreatitis face high risk if they need to have pancreatic fluid drained from their abdomens.
New chronic hepatitis C drugs are easier to use and better tolerated, and more often achieve virologic cure. Newer noninvasive tests help most patients avoid liver biopsy.